PROTACs与寡核酸结合,以应对无法药物治疗的疾病
Guangshuai Zhang1, Si Yan1, Yan Liu1
1School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, P.R.China.
Bioanalysis
|February 3, 2025
概括
基于寡核酸的蛋白质分解向嵌合体 (PROTACs) 为治疗疾病提供了降解以前无法降解的蛋白质的新方法,如转录因子和RNA结合蛋白.
科学领域:
- 生物化学 生化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 无法治疗的目标占人类疾病目标的85%,以平面接口和缺乏结合口袋为特征.
- 传统的制药策略对这些具有挑战性的目标无效.
研究的目的:
- 审查最近使用基于寡核酸的蛋白质分解向仿真体 (PROTACs) 向无药性蛋白质的进展.
- 探索这些新的PROTAC的设计原则和机制.
主要方法:
- 关于寡核酸PROTACs的当前文献的综述.
- 对针对转录因子和RNA结合蛋白的PROTAC设计策略的分析.
- 检查蛋白质酶依赖的降解途径.
主要成果:
- 基于寡核酸的PROTAC在降解以前无法治疗的目标方面表现有前途.
- 这些PROTACs能够对转录因子和RNA结合蛋白进行有针对性的降解.
- 对于与这些目标相关的疾病,正在出现新的治疗策略.
结论:
- 氧核酸-PROTAC技术代表了针对无法药物治疗的蛋白质的重大突破.
- 这种方法为广泛的疾病提供了新的治疗途径.
- 需要对设计和应用进行进一步的研究.
相关概念视频
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Drug Discovery: Overview
7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
GPCR Desensitization
5.7K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Ribozymes
2.5K
2.5K
Carrier-Mediated Transport
239
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
239


